FDA Clears bioMérieux’s Point-of-Care Vaginitis Panel

FDA has granted bioMérieux a dual 510(k) clearance and CLIA waiver for its BIOFIRE SPOTFIRE Vaginitis (VG) Panel, the company announced 22 October 2026 — pairing clearance of the molecular test with the waiver that lets non-laboratory staff run it, so a result that once needed a central lab can now come back from the exam room.

Two clearances, filed as one

A 510(k) clearance says a device is safe and effective for its intended use. A CLIA waiver is a separate determination under the Clinical Laboratory Improvement Amendments: that a test is simple enough and accurate enough to run without the oversight a certified laboratory provides, which is what lets a clinic or urgent-care site operate it without a lab director or medical technologist on staff. Sponsors can pursue them sequentially — clear the device for laboratory use first, then apply for a waiver once it has a track record — or, as bioMérieux did here, file a dual submission that asks FDA to grant both at once. Submitted together, the agency's determinations on device performance and on-site usability moved on the same clock, rather than the waiver trailing a separate review cycle after the clearance.

What the panel tests for, and why the bundle matters

Vaginitis is common and its three leading causes — bacterial vaginosis, yeast infection and trichomoniasis — produce overlapping symptoms that are notoriously hard to tell apart on clinical exam alone. Syndromic multiplex testing, which checks for several possible causes in one run rather than one at a time, is built for exactly that kind of diagnostic ambiguity. Historically, getting a definitive molecular answer meant sending a swab out to a central laboratory and waiting; symptom-based empiric treatment filled the gap in the meantime, with the accuracy problems that implies. A point-of-care result in about 20 minutes, available because the CLIA waiver lets non-laboratory staff run the SPOTFIRE System directly, closes that gap at the visit where the sample is collected.

What's not yet in place

Clearance is not availability. bioMérieux's own timeline targets the beginning of 2027 for US commercial launch, with broader international rollout to follow — a reminder that the regulatory decision and the product actually reaching a clinic shelf are separate milestones, often months apart. The clearance covers point-of-care use in a healthcare setting with either a self-collected or a clinician-collected swab; it does not extend to unsupervised home testing.

Frequently asked questions

What did FDA clear?

bioMérieux's BIOFIRE SPOTFIRE Vaginitis (VG) Panel, a multiplex molecular test that reports eight results covering bacterial vaginosis, yeast (candidiasis) and trichomoniasis from a single vaginal swab in about 20 minutes, run on the company's SPOTFIRE System. FDA granted a dual 510(k) clearance and CLIA waiver together; bioMérieux announced the decision 22 October 2026.

What does the CLIA waiver add?

A CLIA waiver lets non-laboratory healthcare staff run the test at the point of care, rather than requiring it be sent to a certified moderate- or high-complexity laboratory. Clearing the 510(k) and the waiver in a single, dual submission let bioMérieux pursue both at once rather than waiting for a lab-only clearance first.

When did bioMérieux file, and when is it available?

The company submitted the dual 510(k)/CLIA waiver application to FDA on 26 June 2026. Commercial availability in the US is targeted for the beginning of 2027, with a wider international rollout to follow.

Can patients collect their own sample?

Yes. The panel works with both self-collected and clinician-collected vaginal swabs, run in a healthcare setting.